2-(2-氰基苯胺基)-乙酸乙酯 | 87223-76-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(2-氰基苯胺基)-乙酸乙酯
• 英文名称: ethyl 2-((2-cyanophenyl)amino)acetate
• 英文别名: (2-cyanophenylamino)acetic acid ethyl ester；Ethyl 2-(2-cyanoanilino)acetate
• CAS: 87223-76-5
• 化学式: C₁₁H₁₂N₂O₂
• 分子量: 204.228
• InChiKey: SAHHQUFVDZOAEH-UHFFFAOYSA-N

物化性质

• 熔点：
  95-96°C
• 沸点：
  351.1±22.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S36/37
• 危险类别码：
  R20/21/22
• 海关编码：
  2926909090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温且干燥

SDS

Name:	Ethyl 2-(2-cyanoanilino)acetate 97% Material Safety Data Sheet
Synonym:
CAS:	87223-76-5

Section 1 - Chemical Product MSDS Name:Ethyl 2-(2-cyanoanilino)acetate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
87223-76-5	Ethyl 2-(2-cyanoanilino)acetate	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 87223-76-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H12N2O2
Molecular Weight: 204.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 87223-76-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 2-(2-cyanoanilino)acetate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 87223-76-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 87223-76-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 87223-76-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(2-氰基苯胺基)-乙酸乙酯 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 生成 3-氨基-2-吲哚羧酸乙酯
  参考文献：
  名称：

  带有嘧啶并[5,4-b]吲哚和吡唑并[3,4-d]嘧啶基序的双重 Topo II/HDAC 抑制剂的设计、合成和生物学评价

  摘要：

  拓扑异构酶 II (Topo II) 和组蛋白脱乙酰酶 (HDAC) 都是重要的癌症治疗靶点。在这项研究中，设计并合成了两个系列的含有嘧啶并[5,4- b ]吲哚和吡唑并[3,4- d ]嘧啶基序的新型化合物作为双重 Topo II/HDAC 抑制剂。MTT 测定表明，所有化合物均对三种癌细胞系（MGC-803、MCF-7 和 U937）显示出潜在的抗增殖活性，对正常细胞系（3T3）具有低细胞毒性。在酶活性抑制实验中，化合物7d和8d对Topo II和HDAC表现出优异的双重抑制活性。裂解反应测定显示7d是 Topo II 毒物，与对接结果一致。进一步的实验结果表明，化合物7d和8d在MCF-7细胞中可促进细胞凋亡并显着抑制迁移。分子对接显示化合物7d和8d在活性位点结合 Topo II 和 HDAC。分子动力学模拟表明7d可以稳定地结合Topo II和HDAC。

  DOI：

  10.1016/j.ejmech.2023.115303
• 作为产物：
  描述：

  2-氨基苯甲腈 在 三氟乙酸 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 以64%的产率得到2-(2-氰基苯胺基)-乙酸乙酯
  参考文献：
  名称：

  Interleukin-4 gene expression inhibitors

  摘要：

  这项发明揭示并声明了一类吲哚和苯并(b)噻吩衍生物，用于治疗过敏、哮喘、鼻炎、皮炎、B细胞淋巴瘤、肿瘤以及与细菌、鼻病毒或呼吸道合胞病毒(RSV)感染相关的疾病。本发明的化合物由下式(I)定义： 1 其中X、Y、Z、R 1 、R 2 和R 3 如规范中所定义；或其药学上可接受的盐。在本发明的优选实施例中，还揭示并声明了本发明的化合物能够调节T辅助(Th)细胞、Th1/Th2，从而能够抑制白细胞介素-4(IL-4)信息的转录、IL-4的释放或IL-4的产生。

  公开号：

  US20040006123A1

文献信息

• Design, synthesis and biological evaluation of 2-alkoxycarbonyl-3-anilinoindoles as a new class of potent inhibitors of tubulin polymerization
  作者：Romeo Romagnoli、Filippo Prencipe、Paola Oliva、Maria Kimatrai Salvador、Andrea Brancale、Salvatore Ferla、Ernest Hamel、Giampietro Viola、Roberta Bortolozzi、Leentje Persoons、Jan Balzarini、Sandra Liekens、Dominique Schols

  DOI：10.1016/j.bioorg.2020.103665

  日期：2020.4

  A new class of inhibitors of tubulin polymerization based on the 2-alkoxycarbonyl-3-(3',4',5'-trimethoxyanilino)indole molecular skeleton was synthesized and evaluated for antiproliferative activity, inhibition of tubulin polymerization and cell cycle effects. The results presented show that the methoxy substitution and location on the indole nucleus plays an important role in inhibition of cell growth

  合成了基于2-烷氧基羰基-3-（3'，4'，5'-三甲氧基苯胺基）吲哚分子骨架的新型微管蛋白聚合抑制剂，并评估了其抗增殖活性，抑制微管蛋白聚合和细胞周期的作用。给出的结果表明，甲氧基取代和吲哚核上的位置在抑制细胞生长中起着重要作用，最优选的取代基是在C-6处。另外，期望在吲哚核的2-位具有小尺寸的酯官能团（甲氧基/乙氧基羰基）。同样，被甲基，乙基或正丙基烷基化或在N-1吲哚氮上具有苄基部分的类似物保留的活性与在母体N-1H类似物中观察到的活性相同。
• [EN] PYRROLOPYRIMIDINE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE (MDR)<br/>[FR] DERIVES PYRROLOPYRIMIDINIQUES CONVENANT COMME MODULATEURS DE LA MULTIRESISTANCE AUX MEDICAMENTS
  申请人：XENOVA LTD

  公开号：WO2004111052A1

  公开（公告）日：2004-12-23

  A compound which is a pyrrolopyrimidine of formula (I) wherein R1 is selected from H, Cl-C6 alkyl which is unsubstituted or substituted, (CH2)nAr1, (CH2)pNR4R5, halogen and (CH2)pX; R2 is CH2)pArl; R3 is selected from H, Cl -C6 alkyl which is unsubstituted or substituted, (CH2)pZ and (CH2)pArl; P is an unsaturated 5, 6, or 7 membered carbocyclic or heterocyclic ring which is unsubstituted or substituted; R4 and R5 which are the same or different are selected from H, Cl -C6 alkyl which is unsubstituted or substituted, (CH2)nC3-C10 cycloalkyl, (CH2)nAr1 , and (CH2)nOR6, or R4 and R5 together with the nitrogen atom to which they are attached, form a saturated five or six membered nitrogen containing heterocyclic ring which may contain one extra heteroatom selected from 0, N and S and which is unsubstituted or substituted; R6 is selected from H, Cl -C6 alkyl which is unsubstituted or substituted, C3-C10 cycloalkyl, (CH2)nOC1-C6alkyl which is unsubstituted or substituted, (CH2)nO(CH2)nAr1 , (CH2)nCO2C1-C6,alkyl which is unsubstituted or substituted and (CH2)nAr1; X is selected from CN, azide, (CH2)nNHSO2R6 and (CH2)nNHCOR6; Z is selected from CN, CO2R6 and CONR4R5; Ar1 is the same or different when more than one is present within a given substituent group and is an unsaturated C6-C10 membered carbocylic group or an unsaturated 5-11 membered heterocycle, either of which is unsubstituted or substituted; p is an integer of 1 to 6; n is the same or different when more than one is present within a given substituent group and is 0 or an integer of 1 to 6; with the proviso that the pyrrolepyrimidine compound of formula (I) is other than 1-(4-benzyl-piperazin-1-yl)-9H-2,4,9-triaza-fluorene; and the pharmaceutically acceptable salts thereof, have activity as inhibitors of MRP (multidrug resistant protein) and may thus be used to modulate multidrug resistance, for instance in potentiating the cytotoxicity of a chemotherapeutic agent.

  化合物是一种公式为（I）的吡咯吡嘧啶，其中R1从H、未取代或取代的Cl-C6烷基、（CH2）nAr1、（CH2）pNR4R5、卤素和（CH2）pX中选择；R2为（CH2）pArl；R3从H、未取代或取代的Cl-C6烷基、（CH2）pZ和（CH2）pArl中选择；P为未取代或取代的不饱和5、6或7成员碳环或杂环；R4和R5相同或不同，从H、未取代或取代的Cl-C6烷基、（CH2）nC3-C10环烷基、（CH2）nAr1和（CH2）nOR6中选择，或者R4和R5与它们连接的氮原子一起形成饱和的含氮五元或六元杂环，可能含有一个额外的杂原子，选择自O、N和S，未取代或取代；R6从H、未取代或取代的Cl-C6烷基、C3-C10环烷基、（CH2）nOC1-C6烷基、未取代或取代的（CH2）nO（CH2）nAr1、未取代或取代的（CH2）nCO2C1-C6烷基和（CH2）nAr1中选择；X从CN、叠氮、（CH2）nNHSO2R6和（CH2）nNHCOR6中选择；Z从CN、CO2R6和CONR4R5中选择；Ar1当多个存在于给定的取代基组内时相同或不同，为未取代或取代的不饱和C6-C10成员碳环或未取代或取代的不饱和5-11成员杂环；p为1至6的整数；n当多个存在于给定的取代基组内时相同或不同，为0或1至6的整数；但是，公式（I）的吡咯吡嘧啶化合物不是1-（4-苄基哌嗪-1-基）-9H-2,4,9-三氮杂萘；其药学上可接受的盐具有作为MRP（多药耐药蛋白）抑制剂的活性，因此可用于调节多药耐药性，例如在增强化疗药物的细胞毒性方面。
• Certain aryl fused pyrrolopyrimidines; a new class of GABA brain
  申请人：Neurogen Corporation

  公开号：US05326868A1

  公开（公告）日：1994-07-05

  The present invention encompasses structures of the formula: ##STR1## and the pharmaceutically acceptable non-toxic salts thereof wherein: ##STR2## and X represents hydrogen, halogen, or hydroxy; W represents an aryl group unsubstituted or substituted with various organic and inorganic substituents; A, B, C, D, and E represent carbon or nitrogen substituted with hydrogen or various organic and inorganic substituents; and R.sub.3, and R.sub.4 are variables representing various organic and inorganic substituents.. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine drugs, and enhancement of memory.

  本发明涵盖了以下结构的化合物：##STR1##及其药学上可接受的无毒盐，其中：##STR2##和X代表氢、卤素或羟基；W代表未取代或取代有各种有机和无机取代基的芳基；A、B、C、D和E代表碳或氮，取代有氢或各种有机和无机取代基；R.sub.3和R.sub.4是代表各种有机和无机取代基的变量。这些化合物是GABAa脑受体的高度选择性激动剂、拮抗剂或逆拮抗剂，或其前药，可用于焦虑、睡眠和癫痫障碍的诊断和治疗、苯二氮卓类药物过量和记忆增强。
• Indole derivatives as interleukin -4 gene expression inhibitors
  申请人：——

  公开号：US20040010029A1

  公开（公告）日：2004-01-15

  This invention discloses and claims a new class of indole derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. It has now been found that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.

  这项发明揭示并声明了一类新的吲哚衍生物，用于治疗过敏、哮喘、鼻炎、皮炎、B细胞淋巴瘤、肿瘤以及与细菌、鼻病毒或呼吸道合胞病毒（RSV）感染相关的疾病。现在已经发现，该发明的化合物能够调节T辅助细胞（Th）细胞、Th1 / Th2，从而能够抑制白细胞介素-4（IL-4）信息的转录、IL-4释放或IL-4的产生。
• INTERLEUKIN-4 GENE EXPRESSION INHIBITORS
  申请人：ALKAN Sefik S.

  公开号：US20080132481A1

  公开（公告）日：2008-06-05

  This invention discloses and claims a class of indole and benzo(b)thiophene derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. The compounds of this invention are defined by the Formula (I): wherein X, Y, Z, R 1 , R 2 and R 3 are as defined in the specification; or a pharmaceutically acceptable salt thereof. In preferred embodiments of this invention it is also disclosed and claimed that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.

  本发明揭示和声明了一类用于治疗过敏、哮喘、鼻炎、皮炎、B细胞淋巴瘤、肿瘤以及与细菌、鼻病毒或呼吸道合胞病毒（RSV）感染相关的疾病的吲哚和苯并(b)噻吩衍生物。本发明的化合物由公式（I）定义：其中X、Y、Z、R1、R2和R3如规范中所定义；或其药学上可接受的盐。在本发明的优选实施例中，还揭示和声明本发明的化合物能够调节T辅助（Th）细胞，Th1 / Th2，并能够抑制白细胞介素-4（IL-4）信息的转录、IL-4的释放或IL-4的产生。